InBioGen Co Ltd (101140) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.010x

Based on the latest financial reports, InBioGen Co Ltd (101140) has a cash flow conversion efficiency ratio of -0.010x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-1.67 Billion ≈ $-1.13 Million USD) by net assets (₩170.78 Billion ≈ $115.73 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

InBioGen Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how InBioGen Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read InBioGen Co Ltd debt and liabilities for a breakdown of total debt and financial obligations.

InBioGen Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of InBioGen Co Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Frontier Nuclear and Minerals Inc.
NASDAQ:FNUC
N/A
RTG Mining Inc
AU:RTG
0.000x
Datagate Bilgisayar Malzemeleri Ticaret AS
IS:DGATE
1.726x
Country Group Holdings Public Company Limited
BK:CGH
-0.037x
Talaad Thai Leasehold Property Fund
BK:TTLPF
0.039x
Chang Type Industrial Co Ltd
TW:1541
0.021x
Quartiers Properties AB (publ)
ST:QUART-PREF
0.048x
Powertech Industrial Co Ltd
TW:3296
-0.016x

Annual Cash Flow Conversion Efficiency for InBioGen Co Ltd (2013–2024)

The table below shows the annual cash flow conversion efficiency of InBioGen Co Ltd from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see InBioGen Co Ltd market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 ₩159.84 Billion
≈ $108.32 Million
₩-33.13 Million
≈ $-22.45K
0.000x +97.07%
2023-12-31 ₩148.68 Billion
≈ $100.76 Million
₩-1.05 Billion
≈ $-712.04K
-0.007x +93.59%
2022-12-31 ₩104.42 Billion
≈ $70.76 Million
₩-11.51 Billion
≈ $-7.80 Million
-0.110x -177.48%
2021-12-31 ₩178.02 Billion
≈ $120.64 Million
₩-7.07 Billion
≈ $-4.79 Million
-0.040x +61.49%
2020-12-31 ₩77.91 Billion
≈ $52.80 Million
₩-8.03 Billion
≈ $-5.44 Million
-0.103x -77.77%
2019-12-31 ₩66.00 Billion
≈ $44.72 Million
₩-3.83 Billion
≈ $-2.59 Million
-0.058x +20.27%
2018-12-31 ₩23.35 Billion
≈ $15.83 Million
₩-1.70 Billion
≈ $-1.15 Million
-0.073x -93.19%
2017-12-31 ₩11.32 Billion
≈ $7.67 Million
₩-426.44 Million
≈ $-288.99K
-0.038x -162.82%
2016-12-31 ₩5.75 Billion
≈ $3.90 Million
₩344.75 Million
≈ $233.63K
0.060x +104.27%
2015-12-31 ₩7.80 Billion
≈ $5.29 Million
₩-10.96 Billion
≈ $-7.43 Million
-1.405x -732.60%
2014-12-31 ₩4.12 Billion
≈ $2.79 Million
₩-695.95 Million
≈ $-471.63K
-0.169x +45.32%
2013-12-31 ₩3.67 Billion
≈ $2.49 Million
₩-1.13 Billion
≈ $-767.47K
-0.309x --

About InBioGen Co Ltd

KO:101140 Korea Footwear & Accessories
Market Cap
$59.48 Million
₩87.77 Billion KRW
Market Cap Rank
#21225 Global
#1338 in Korea
Share Price
₩8790.00
Change (1 day)
+2.57%
52-Week Range
₩7800.00 - ₩14650.00
All Time High
₩14650.00
About

INBIOGEN Co., Ltd. engages in the manufacture and distribution of footwear products in South Korea. It is also involved in distribution of wood pellets; kiosk; and food and beverage businesses. The company was formerly known as BTONE CO.,Ltd. INBIOGEN Co., Ltd. was founded in 1949 and is headquartered in Seoul, South Korea.